Testing silevertinib added to temozolomide for newly diagnosed glioblastoma
Official title: Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This trial is testing whether adding a drug called silevertinib to temozolomide works better than temozolomide alone.
Read our full plain-language summary
What the trial team says
The purpose of this study is to see if combining silevertinib with temozolomide after surgery and radiotherapy helps treat newly diagnosed glioblastoma (GBM) better than using temozolomide alone in the maintenance setting. Specifically, this study is being done to find answers to the following questions: * How much of the study drugs (silevertinib combined with temozolomide) should be given to participants with GBM? * What are the side effects participants have when taking the study drug (silevertinib combined with temozolomide)? * Can the study drug (silevertinib combined with temozolomide) help participants with GBM live longer without disease progression compared to treatment with temozolomide alone?
Key facts
- Registry number
- NCT07326566
- Stage of testing
- Phase 2
- Conditions studied
- Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM), Glioma, Central Nervous System Diseases, Brain Cancer
Where it is running
This trial lists 27 sites.
-
Alabama
- University of Alabama at Birmingham O'Neal Comprehensive Cancer Center (Birmingham)
-
Arkansas
- Highlands Oncology Group (Springdale)
-
California
- Cedars-Sinai Medical Center (Los Angeles)
- Stanford University (Palo Alto)
-
Connecticut
- Yale Cancer Center (New Haven)
-
District of Columbia
- Johns Hopkins Sibley Memorial Hospital (Washington D.C.)
-
Florida
- Miami Cancer Institute (Miami)
- Moffitt Cancer Center (Tampa)
-
Maryland
- Johns Hopkins Sidney Kimmel Cancer Center - Baltimore (Baltimore)
-
Massachusetts
- Massachusetts General Hospital (Boston)
- Beth Israel Deaconess Medical Center (Boston)
- Dana Farber Cancer Institute (Boston)
-
Michigan
- Henry Ford Cancer- Detroit (Detroit)
-
Missouri
- Washington University School of Medicine Siteman Cancer Center (St Louis)
-
New Jersey
- John Theurer Cancer Center at Hackensack University Medical Center (Hackensack)
- Rutgers Cancer Institute (New Brunswick)
- Atlantic Health (Summit)
-
New York
- Northwell Health Center for Advanced Medicine - Brain Tumor Center (Lake Success)
- Columbia University Irving Medical Center (New York)
- Montefiore Medical Center (The Bronx)
-
Ohio
- Ohio State University (Columbus)
-
Pennsylvania
- Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center (Philadelphia)
- UPMC Hillman Cancer Center (Pittsburgh)
-
South Carolina
- Prisma Health (Greenville)
-
Utah
- Huntsman Cancer Institute, University of Utah (Salt Lake City)
-
Virginia
- Inova Schar Cancer Institute (Fairfax)
- VCU Massey Comprehensive Cancer Center (Richmond)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.